1. Home
  2. LOAN vs CTSO Comparison

LOAN vs CTSO Comparison

Compare LOAN & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Manhattan Bridge Capital Inc

LOAN

Manhattan Bridge Capital Inc

HOLD

Current Price

$4.39

Market Cap

51.9M

Sector

Real Estate

ML Signal

HOLD

Logo Cytosorbents Corporation

CTSO

Cytosorbents Corporation

HOLD

Current Price

$0.74

Market Cap

45.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LOAN
CTSO
Founded
1989
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Medical/Dental Instruments
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
51.9M
45.7M
IPO Year
1999
2008

Fundamental Metrics

Financial Performance
Metric
LOAN
CTSO
Price
$4.39
$0.74
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$5.38
AVG Volume (30 Days)
19.0K
62.9K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
10.02%
N/A
EPS Growth
2.08
N/A
EPS
0.35
N/A
Revenue
$9,688,641.00
$22,503,908.00
Revenue This Year
N/A
$7.29
Revenue Next Year
$4.47
$8.91
P/E Ratio
$12.52
N/A
Revenue Growth
N/A
48.53
52 Week Low
$4.29
$0.60
52 Week High
$6.05
$1.39

Technical Indicators

Market Signals
Indicator
LOAN
CTSO
Relative Strength Index (RSI) 31.35 65.19
Support Level $4.29 $0.61
Resistance Level $4.59 $1.02
Average True Range (ATR) 0.06 0.04
MACD -0.00 0.01
Stochastic Oscillator 8.97 91.86

Price Performance

Historical Comparison
LOAN
CTSO

About LOAN Manhattan Bridge Capital Inc

Manhattan Bridge Capital Inc is a real estate finance company taxed as a REIT that specializes in originating, servicing and managing a portfolio of first mortgage loans. The company offers short-term, secured, non-banking loans which may renew or extend, before or after their initial term expires, to real estate investors to fund their acquisition, renovation, rehabilitation or development of residential or commercial properties located in the New York metropolitan area, including New Jersey and Connecticut, and in Florida.

About CTSO Cytosorbents Corporation

CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.

Share on Social Networks: